J. Goldman & CO LP Krystal Biotech, Inc. Transaction History

J. Goldman & CO LP

$2.89 Billion
Q1 2024

A detailed history of J. Goldman & CO LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 20,963 shares of KRYS stock, worth $3.85 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

20,963

Previous 5,408 287.63%

Holding current value

$3.85 Million

Previous $670,000 456.57%

% of portfolio

0.13%

Previous 0.03%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $1.68 Million - $2.79 Million	15,555 Added 287.63%	20,963 $3.73 Million
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $2.86 Million - $3.82 Million	-29,805 Reduced 84.64%	5,408 $670,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $3.24 Million - $3.89 Million	29,864 Added 558.31%	35,213 $4.08 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $207,972 - $345,348	2,650 Added 98.18%	5,349 $627,000
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $1.2 Million - $1.4 Million	-16,620 Reduced 86.03%	2,699 $216,000

Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $593,010 - $750,420	9,392 Added 94.61%	19,319 $1.53 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $263,485 - $334,791	-4,063 Reduced 29.04%	9,927 $692,000
Q2 2022 Aug 15, 2022	SELL	$48.93 - $73.47 $874,330 - $1.31 Million	-17,869 Reduced 56.09%	13,990 $919,000
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $1.66 Million - $2.3 Million	31,859 New	31,859 $2.12 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $250,803 - $555,912	-6,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$52.01 - $71.77 $241,898 - $333,802	-4,651 Reduced 42.47%	6,300 $329,000
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $4,722 - $6,218	76 Added 0.7%	10,951 $745,000
Q1 2021 May 17, 2021	SELL	$59.42 - $85.46 $329,365 - $473,704	-5,543 Reduced 33.76%	10,875 $838,000
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $701,202 - $1.06 Million	-17,254 Reduced 51.24%	16,418 $985,000
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $435,372 - $559,089	-11,530 Reduced 25.51%	33,672 $1.45 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $1.67 Million - $2.71 Million	45,202 New	45,202 $1.87 Million

Others Institutions Holding KRYS

# of Institutions

262

Shares Held

21.5M

Call Options Held

462K

Put Options Held

723K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.71B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account